glp-1 agonists with cardiovascular benefit Effects of Glucagon-Like Peptide-1 Receptor Could GLP-1 medications be helpful
Description
doi: 10.2147/DDDT.S506957, 101 Montrose-RafizadehC.EganJ
Methodology Study design This study is a systematic review and meta-analysis of cardiovascular outcome trials (CVOTs) evaluating the long-term safety and efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in populations at high cardiovascular risk
Zepbound is approved by the FDA as a weight loss management treatment for people with obesity or those who are overweight with at least one weight-related condition such as high blood pressure
Editors Note: This article was first published on Jan
C., Amiel, S
